Line 1,183:
Line 1,183:
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30110-3/fulltext Mateos et al. 2019 (KEYNOTE-183)]
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30110-3/fulltext Mateos et al. 2019 (KEYNOTE-183)]
|2016-2017
|2016-2017
− |style="background-color:#1a9851"|Phase III (E-esc)
+ |style="background-color:#1a9851"|Phase 3 (E-esc)
|[[Multiple_myeloma,_relapsed-refractory#Pomalidomide_.26_Dexamethasone_.28PD.29|PD]]
|[[Multiple_myeloma,_relapsed-refractory#Pomalidomide_.26_Dexamethasone_.28PD.29|PD]]
| style="background-color:#fc8d59" |Seems to have inferior PFS <br>(HR 1.53, 95% CI 1.05-2.22)
| style="background-color:#fc8d59" |Seems to have inferior PFS <br>(HR 1.53, 95% CI 1.05-2.22)
Line 1,626:
Line 1,626:
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30178-0/fulltext Vergote et al. 2019 (TRINOVA-3)]
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30178-0/fulltext Vergote et al. 2019 (TRINOVA-3)]
|2012-2014
|2012-2014
− |style="background-color:#1a9851"|Phase III (E-esc)
+ |style="background-color:#1a9851"|Phase 3 (E-esc)
|[[Ovarian_cancer#Carboplatin_.26_Paclitaxel_.28CP.29_3|TC]]
|[[Ovarian_cancer#Carboplatin_.26_Paclitaxel_.28CP.29_3|TC]]
|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS <br>(HR 0.93, 95% CI 0.79-1.09)
|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS <br>(HR 0.93, 95% CI 0.79-1.09)
Line 1,749:
Line 1,749:
|[https://www.ejcancer.com/article/S0959-8049(16)32425-X/fulltext Marth et al. 2016 (TRINOVA-2)]
|[https://www.ejcancer.com/article/S0959-8049(16)32425-X/fulltext Marth et al. 2016 (TRINOVA-2)]
|2011-2013
|2011-2013
− |style="background-color:#1a9851"|Phase III (E-esc)
+ |style="background-color:#1a9851"|Phase 3 (E-esc)
|[[Ovarian_cancer#Doxorubicin_pegylated_liposomal_monotherapy|PLD]]
|[[Ovarian_cancer#Doxorubicin_pegylated_liposomal_monotherapy|PLD]]
|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS <br>(HR 0.92, 95% CI 0.68-1.24)
|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS <br>(HR 0.92, 95% CI 0.68-1.24)
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the HemOnc Ontology and for historic interest.
Contents
1 Regimens composed solely of approved drugs
1.1 3M
1.2 5-FU & RT
1.3 7+3i & Clofarabine
1.4 7+3i & Lenalidomide
1.5 7+4i
1.6 7+5d
1.7 Abiraterone & Enzalutamide
1.8 ABVP
1.9 ACP
1.10 Afatinib & Vinorelbine
1.11 A-ICE
1.12 AME
1.13 Amsacrine & IDAC
1.14 ATRA, Cytarabine, Etoposide
1.15 AVML
1.16 Binimetinib monotherapy
1.17 Bortezomib & Bevacizumab
1.18 Bortezomib & Siltuximab
1.19 BTH (Taxotere)
1.20 BTOC
1.21 CAD
1.22 Capecitabine & Cisplatin (CX) & Bevacizumab
1.23 Capecitabine & Cisplatin (CX) & Ramucirumab
1.24 Capecitabine & Ruxolitinib
1.25 Capecitabine & Sorafenib
1.26 Capecitabine & Sunitinib
1.27 Capecitabine & Vinflunine
1.28 Capecitabine & Vinorelbine
1.29 Capecitabine, Cisplatin, Cetuximab, RT
1.30 Capecitabine, Erlotinib, RT
1.31 CarboMIP
1.32 Carboplatin & Epirubicin
1.33 Carboplatin & Paclitaxel (CP) & Bexarotene
1.34 Carboplatin & Paclitaxel (CP) & Cetuximab
1.35 Carboplatin & Paclitaxel (CP) & Erlotinib
1.36 Carboplatin & Paclitaxel (CP) & PLD
1.37 Carboplatin & Paclitaxel (CP) & Sorafenib
1.38 Carboplatin & Paclitaxel (CP) & Topotecan
1.39 Carboplatin & Topotecan
1.40 CBM
1.41 CCG
1.42 Carboplatin & Etoposide (CE) & Ipilimumab
1.43 Carboplatin & Etoposide (CE) & Thalidomide
1.44 CIB
1.45 Cisplatin & Methotrexate
1.46 Cisplatin & Treosulfan
1.47 Cisplatin & Vincristine
1.48 Cisplatin, Avelumab, RT
1.49 Cisplatin, Pemetrexed, RT
1.50 CODE
1.51 CYVADIC
1.52 DBCT
1.53 Docetaxel & Gefitinib
1.54 Docetaxel & Lapatinib
1.55 Docetaxel & Pertuzumab
1.56 Docetaxel & Selumetinib
1.57 Docetaxel & Sunitinib
1.58 Docetaxel & ziv-Aflibercept
1.59 Doxorubicin & Etoposide
1.60 Doxorubicin & Paclitaxel
1.61 Doxorubicin & Sorafenib
1.62 Doxorubicin & Streptozocin
1.63 Doxorubicin & Vinorelbine
1.64 EAP
1.65 ECVBP
1.66 ELF
1.67 Encorafenib monotherapy
1.68 EP & Ipilimumab
1.69 EP, Tamoxifen, RT
1.70 Erlotinib & Sunitinib
1.71 Everolimus & Vinorelbine
1.72 E-GEMOX
1.73 FAP
1.74 FEC & HP
1.75 FLA
1.76 FLAG-Ida & GO
1.77 FLAI
1.78 FOLF-CB
1.79 FOLFIRI & Regorafenib
1.80 FOLFIRI & Simvastatin
1.81 FOLFIRI & Sunitinib
1.82 FULV & Trimetrexate
1.83 GVP
1.84 ICE, ATRA, GO
1.85 Ixabepilone & Bevacizumab
1.86 ME
1.87 MEV
1.88 MFL
1.89 MFT
1.90 Mitoxantrone & Hydrocortisone
1.91 MMF
1.92 MPP
1.93 MTP
1.94 MVC
1.95 NIP
1.96 PD & Pembrolizumab
1.97 PEI
1.98 PELF
1.99 PGT
1.100 PGV
1.101 Pemetrexed & Cetuximab
1.102 Pemetrexed & Vandetanib
1.103 Pixantrone & Rituximab
1.104 PVI
1.105 R-BEACOPP
1.106 R-MegaCHOEP
1.107 Realgar-Indigo naturalis formula monotherapy
1.108 TCG
1.109 TCHL (Taxotere)
1.110 TCL (Taxotere)
1.111 TEC
1.112 TG+Bev
1.113 TH (Taxol) & Everolimus
1.114 TL (Taxotere)
1.115 TPCV
1.116 TX+Bev
1.117 VADx
1.118 VAPEC-B
1.119 VBM (Vinblastine)
1.120 VCE
1.121 Vinorelbine & Hydrocortisone
1.122 VNC
1.123 VPV
1.124 VTDC
2 Regimens that contain experimental (unapproved) drugs
Regimens composed solely of approved drugs
3M
3M: M itomycin, M itoxantrone, M ethotrexate
Regimen
Chemotherapy
5-FU & RT
Regimen
Chemotherapy
Radiotherapy
7+3i & Clofarabine
7+3i & Clofarabine: 7 days of cytarabine, 3 days of i darubicin, Clofarabine
Regimen
Chemotherapy
7+3i & Lenalidomide
7+3i & Lenalidomide: 7 days of cytarabine, 3 days of i darubicin, Lenalidomide
Regimen
Chemotherapy
Targeted therapy
7+4i
7+4i: 7 days of cytarabine, 4 days of i darubicin
Regimen
Chemotherapy
7+5d
7+5d: 7 days of cytarabine, 5 days of d aunorubicin
Regimen
Chemotherapy
Abiraterone & Enzalutamide
Regimen
Endocrine therapy
ABVP
Regimen
Chemotherapy
ACP
ACP: A tezolizumab, C arboplatin, P aclitaxel
Regimen
Immunotherapy
Chemotherapy
Afatinib & Vinorelbine
Regimen
Chemotherapy
Targeted therapy
A-ICE
A-ICE: A TRA, I darubicin, C ytarabine, E toposide
Regimen
Targeted therapy
Chemotherapy
AME
AME: A ra-C (Cytarabine), M itoxantrone, E toposide
Regimen
Chemotherapy
Amsacrine & IDAC
Amsacrine & IDAC: Amsacrine & I ntermediate D ose A ra-C (Cytarabine)
Regimen
Chemotherapy
ATRA, Cytarabine, Etoposide
Regimen
Targeted therapy
Chemotherapy
AVML
Regimen
Chemotherapy
Supportive therapy
Binimetinib monotherapy
Regimen
Targeted therapy
Bortezomib & Bevacizumab
Regimen
Targeted therapy
Bortezomib & Siltuximab
Regimen
Targeted therapy
BTH (Taxotere)
BTH: B evacizumab, T axotere (Docetaxel), H erceptin (Trastuzumab)
Regimen
Chemotherapy
Targeted therapy
BTOC
BTOC: B CNU, T hiotepa, O ncovin (Vincristine), C yclophosphamide
Regimen
Chemotherapy
CAD
CAD: C yclophosphamide, A driamycin (Doxorubicin), D DP (Cisplatin)
Regimen
Chemotherapy
Capecitabine & Cisplatin (CX) & Bevacizumab
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Cisplatin (CX) & Ramucirumab
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Ruxolitinib
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Sorafenib
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Sunitinib
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Vinflunine
Regimen
Chemotherapy
Capecitabine & Vinorelbine
NX: N avelbine (Vinorelbine) & X eloda (Capecitabine)
Regimen
Chemotherapy
Capecitabine, Cisplatin, Cetuximab, RT
Regimen
Chemotherapy
Targeted therapy
Radiotherapy
Capecitabine, Erlotinib, RT
Regimen
Chemotherapy
Targeted therapy
Radiotherapy
CarboMIP
CarboMIP: Carbo platin, M itomycin, I fosfamide, P latinol (Cisplatin)
Regimen
Chemotherapy
Carboplatin & Epirubicin
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Bexarotene
CP & Bexarotene: C arboplatin, P aclitaxel, Bexarotene
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Cetuximab
CP & Cetuximab: C arboplatin, P aclitaxel, Cetuximab
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Erlotinib
CP & Erlotinib: C arboplatin, P aclitaxel, Erlotinib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & PLD
TC & PLD: T axol (Paclitaxel), C arboplatin, P egylated L iposomal D oxorubicin
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Sorafenib
CP & Sorafenib: C arboplatin, P aclitaxel, Sorafenib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Topotecan
TC & Topotecan: T axol (Paclitaxel), C arboplatin, Topotecan
Regimen
Chemotherapy
Carboplatin & Topotecan
Regimen
Chemotherapy
CBM
CBM: C apecitabine, B evacizumab, M itomycin
Regimen
Chemotherapy
Targeted therapy
CCG
CCG: C isplatin, C arboplatin, G emcitabine
Regimen
Chemotherapy
Carboplatin & Etoposide (CE) & Ipilimumab
CE & Ipilimumab: C arboplatin, E toposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
Carboplatin & Etoposide (CE) & Thalidomide
CE & Thalidomide: C arboplatin, E toposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
CIB
CIB: C isplatin, I fosfamide, B leomycin
Regimen
Chemotherapy
Cisplatin & Methotrexate
Regimen
Chemotherapy
Cisplatin & Treosulfan
Regimen
Chemotherapy
Cisplatin & Vincristine
Regimen
Chemotherapy
Cisplatin, Avelumab, RT
Regimen
Chemotherapy
Immunotherapy
Radiotherapy
Cisplatin, Pemetrexed, RT
Regimen
Chemotherapy
Radiotherapy
CODE
CODE: C isplatin, O ncovin (Vincristine), D oxorubicin, E toposide
Regimen
Chemotherapy
CYVADIC
CYVADIC: CY clophosphamide, V incristine, AD riamycin (Doxorubicin), I midazole C arboxamide (Dacarbazine)
Regimen
Chemotherapy
DBCT
DBCT: D acarbazine, B CNU (Carmustine), C isplatin, T amoxifen
Regimen
Chemotherapy
Endocrine therapy
Docetaxel & Gefitinib
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Lapatinib
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Pertuzumab
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Selumetinib
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Sunitinib
Regimen
Chemotherapy
Targeted therapy
Docetaxel & ziv-Aflibercept
Regimen
Chemotherapy
Targeted therapy
Doxorubicin & Etoposide
Regimen
Chemotherapy
Doxorubicin & Paclitaxel
Regimen
Chemotherapy
Doxorubicin & Sorafenib
Regimen
Chemotherapy
Targeted therapy
Doxorubicin & Streptozocin
Regimen
Chemotherapy
Doxorubicin & Vinorelbine
Regimen
Chemotherapy
EAP
EAP: E toposide, A driamycin (Doxorubicin), P latinol (Cisplatin)
Regimen
Chemotherapy
ECVBP
ECVBP: E pirubicin, C yclophosphamide, V indesine, B leomycin, P rednisone
Regimen
Chemotherapy
ELF
ELF: E toposide, L eucovorin, 5-F U
Regimen
Chemotherapy
Encorafenib monotherapy
Regimen
Targeted therapy
EP & Ipilimumab
EP & Ipilimumab: E toposide, P latinol (Cisplatin), Ipilimumab
Regimen
Chemotherapy
Immunotherapy
EP, Tamoxifen, RT
EP, Tamoxifen, RT: E toposide, P latinol (Cisplatin), Tamoxifen, R adiation T herapy
Regimen
Chemotherapy
Endocrine therapy
Radiotherapy
Erlotinib & Sunitinib
Regimen
Targeted therapy
Everolimus & Vinorelbine
Regimen
Chemotherapy
Targeted therapy
E-GEMOX
E-GEMOX: E rlotinib, GEM citabine, OX aliplatin
Regimen
Targeted therapy
Chemotherapy
FAP
FAP: F luorouracil, A lfa interferon, P latinol (Cisplatin)
Regimen
Chemotherapy
Immunotherapy
FEC & HP
FEC & HP: F luorouracil, E pirubicin, C yclophosphamide, H erceptin (Trastuzumab), P ertuzumab
Regimen
Chemotherapy
Targeted therapy
FLA
FLA: FL udarabine & A ra-C (Cytarabine)
Regimen
Chemotherapy
FLAG-Ida & GO
FLAG-Ida & GO: FL udarabine, A ra-C (Cytarabine), G -CSF (Lenograstim), Ida rubicin, G emtuzumab O zogamicin
Regimen
Chemotherapy
Growth factor therapy
Targeted therapy
FLAI
FLAI: FL udarabine, A ra-C (Cytarabine), I darubicin
FIA: F ludarabine, I darubicin, A ra-C (Cytarabine)
Regimen
Chemotherapy
FOLF-CB
FOLF-CB: FOL inic acid, F luorouracil, C etuximab, B evacizumab
Regimen
Chemotherapy
Targeted therapy
FOLFIRI & Regorafenib
FOLFIRI & Regorafenib: FOL inic acid, F luorouracil, IRI notecan, Regorafenib
Regimen
Chemotherapy
Targeted therapy
FOLFIRI & Simvastatin
FOLFIRI & Simvastatin: FOL inic acid, F luorouracil, IRI notecan, Simvastatin
Regimen
Chemotherapy
Targeted therapy
FOLFIRI & Sunitinib
FOLFIRI & Sunitinib: FOL inic acid, F luorouracil, IRI notecan, Sunitinib
Regimen
Chemotherapy
Targeted therapy
FULV & Trimetrexate
FULV & Trimetrexate: 5-FU & L eucoV orin (Folinic acid), Trimetrexate
Regimen
Chemotherapy
GVP
GVP: G emcitabine, V inorelbine, P latinol (Cisplatin)
Regimen
Chemotherapy
ICE, ATRA, GO
ICE, ATRA: I darubicin, C ytarabine, E toposide, A ll-T rans R etinoic A cid, G emtuzumab O zogamicin
Regimen
Chemotherapy
Targeted therapy
Ixabepilone & Bevacizumab
Regimen
Chemotherapy
Targeted therapy
ME
ME: M itoxantrone & E toposide
Regimen
Chemotherapy
MEV
MEV: M itomycin, E toposide, V indesine
Regimen
Chemotherapy
MFL
MFL: M ethyl-lomustine (MeCCNU), 5-F U, L eucovorin (Folinic acid)
Regimen
Chemotherapy
MFT
MFL: M ethotrexate, 5-F U, T amoxifen
Regimen
Chemotherapy
Endocrine therapy
Mitoxantrone & Hydrocortisone
Regimen
Chemotherapy
Endocrine therapy
MMF
MMF: M ethyl-lomustine (MeCCNU), M itomycin, 5-F U
Regimen
Chemotherapy
MPP
MPP: M elphalan, P rednisone, P rocarbazine
Regimen
Chemotherapy
MTP
MTP: M yocet (Non-pegylated liposomal doxorubicin), T rastuzumab, P aclitaxel
Regimen
Chemotherapy
Targeted therapy
MVC
MVC: M itomycin, V indesine, C arboplatin
Regimen
Chemotherapy
NIP
NIP: N avelbine (Vinorelbine), I fosfamide, P latinol (Cisplatin)
Regimen
Chemotherapy
PD & Pembrolizumab
PD & Pembrolizumab: P omalidomide, D examethasone, Pembrolizumab
Regimen
Targeted therapy
Chemotherapy
Immunotherapy
PEI
PEI: P latinol (Cisplatin), E toposide, I fosfamide
Regimen
Chemotherapy
PELF
PELF: P latinol (Cisplatin), E pirubicin, L eucovorin, 5-F U
Regimen
Chemotherapy
PGT
PGT: P latinol (Cisplatin), G emcitabine, T axol (Paclitaxel)
Regimen
Chemotherapy
PGV
PGV: P latinol (Cisplatin), G emcitabine, V inorelbine
CGV: C isplatin, G emcitabine, V inorelbine
Regimen
Chemotherapy
Pemetrexed & Cetuximab
Regimen
Chemotherapy
Targeted therapy
Pemetrexed & Vandetanib
Regimen
Chemotherapy
Targeted therapy
Pixantrone & Rituximab
Regimen
Chemotherapy
Targeted therapy
PVI
PVI: P latinol (Cisplatin), V indesine, I fosfamide
VIP: V indesine, I fosfamide, P latinol (Cisplatin)
Regimen
Chemotherapy
R-BEACOPP
R-BEACOPP: R ituximab, B leomycin, E toposide, A driamycin (Doxorubicin), C yclophosphamide, O ncovin (Vincristine), P rocarbazine, P rednisone
Regimen
Targeted therapy
Chemotherapy
R-MegaCHOEP
R-MegaCHOEP: R ituximab, high-dose (Mega ) C yclophosphamide, H ydroxydaunorubicin (Doxorubicin), O ncovin (Vincristine), E toposide, P rednisone
Targeted therapy
Chemotherapy
Realgar-Indigo naturalis formula monotherapy
Regimen
Targeted therapy
TCG
TCG: T axol (Paclitaxel), C arboplatin, G emcitabine
Regimen
Chemotherapy
TCHL (Taxotere)
TCHL: T axotere (Docetaxel), C arboplatin, H erceptin (Trastuzumab), L apatinib
Regimen
Chemotherapy
Targeted therapy
TCL (Taxotere)
TCL: T axotere (Docetaxel), C arboplatin, L apatinib
Regimen
Chemotherapy
Targeted therapy
TEC
TEC: T axol (Paclitaxel), E pirubicin, C arboplatin
Regimen
Chemotherapy
TG+Bev
TG+Bev: T axotere (Docetaxel), G emcitabine, Bev acizumab
Regimen
Chemotherapy
Targeted therapy
TH (Taxol) & Everolimus
TH & Everolimus: T axol (Paclitaxel), H erceptin (Trastuzumab), Everolimus
Regimen
Chemotherapy
Targeted therapy
TL (Taxotere)
TL: T axotere (Docetaxel) & L apatinib
Regimen
Chemotherapy
Targeted therapy
TPCV
TPCV: T hioguanine, P rocarbazine, C CNU, V incristine
Regimen
Chemotherapy
TX+Bev
TX+Bev: T axotere (Docetaxel), X eloda (Capecitabine), Bev acizumab
Regimen
Chemotherapy
Targeted therapy
VADx
VADx: V incristine, A ra-C (Cytarabine), D ex amethasone
Regimen
Chemotherapy
VAPEC-B
VAPEC-B: V incristine, A driamycin (Doxorubicin), P rednisolone, E toposide, C yclophosphamide, B leomycin
Regimen
Chemotherapy
VBM (Vinblastine)
VBM: V inblastine, B leomycin, M ethotrexate
Regimen
Chemotherapy
VCE
VCE: V incristine, C arboplatin, E toposide
Regimen
Chemotherapy
Vinorelbine & Hydrocortisone
Regimen
Chemotherapy
Endocrine therapy
VNC
VNC: V incristine, N ovantrone (Mitoxantrone), C yclophosphamide
Regimen
Chemotherapy
VPV
VPV: V inblastine, P latinol (Cisplatin), V P-16 (Etoposide)
Regimen
Chemotherapy
VTDC
VTDC: V elcade (Bortezomib), T halidomide, D examethasone, C yclophosphamide
Regimen
Targeted therapy
Chemotherapy
Regimens that contain experimental (unapproved) drugs
Adavosertib & Gemcitabine
Regimen
Targeted therapy
Chemotherapy
Alisertib monotherapy
Regimen
Targeted therapy
Amonafide & Cytarabine
Regimen
Chemotherapy
Buparlisib & Fulvestrant
Regimen
Targeted therapy
Endocrine therapy
Buparlisib & Paclitaxel
Regimen
Targeted therapy
Chemotherapy
Carboplatin & Paclitaxel (CP) & Cediranib
CP & Cediranib: C arboplatin, P aclitaxel, Cediranib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Trebananib
TC & Trebananib: T axol (Paclitaxel), C arboplatin, Trebananib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Veliparib
CP & Veliparib: C arboplatin, P aclitaxel, Veliparib
Regimen
Chemotherapy
Targeted therapy
Cediranib monotherapy
Regimen
Targeted therapy
Docetaxel & Bavituximab
Regimen
Chemotherapy
Immunotherapy
Docetaxel & Ganetespib
Regimen
Chemotherapy
Targeted therapy
Erlotinib & Figitumumab
Regimen
Targeted therapy
Erlotinib & Onartuzumab
Regimen
Targeted therapy
Erlotinib & Tivantinib
Regimen
Targeted therapy
Cisplatin & Gemcitabine (GC) & Veliparib
GC & Veliparib: G emcitabine, C isplatin, Veliparib
Regimen
Chemotherapy
Targeted therapy
Ibrutinib & Ublituximab
Regimen
Targeted therapy
PLD & Trebananib
Regimen
Chemotherapy
Targeted therapy